


RealRate

## PHARMACEUTICAL 2021

## 89bio Inc. Rank 102 of 409





## PHARMACEUTICAL 2021



## 89bio Inc. Rank 102 of 409

The relative strengths and weaknesses of 89bio Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of 89bio Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 292% points. The greatest weakness of 89bio Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 48% points.

The company's Economic Capital Ratio, given in the ranking table, is 20%, being 375% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	210,202
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,113
Liabilities, Non-Current	0
Other Assets	706
Other Compr. Net Income	-10
Other Expenses	-59
Other Liabilities	0
Other Net Income	-203
Property and Equipment	166
Research and Development	36,199
Revenues	0
Selling, General and Administrative Expense	13,156

Output Variable	Value in 1000 USD
Assets	211,074
Liabilities	8,113
Expenses	49,296
Stockholders Equity	202,961
Net Income	-49,499
Comprehensive Net Income	-49,504
Economic Capital Ratio	20%